{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE189nnn/GSE189489/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE189489"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"RNAseq data of mouse B16-F10 melanoma cell lines after siEzh2 knockdown or GSK126 methyl-transferase inhibitor or DZNep treatment","description":"Enhancer of zeste homolog 2 (EZH2) plays critical roles in the progression of many malignancies including melanoma. The most well-known EZH2 mechanism is regulating gene expression through catalysing tri-methylation of histone H3 at Lys 27 (H3K27me3). However, EZH2 also have methylation-independent activities that limit the therapeutic potential of EZH2 methyl-transferase inhibitors. To investigate the methyl-transferase independent role of EZH2 in melanoma, we performed global gene expression analysis of B16-F10 cells treated with methyl-transferase inhibitor GSK126 or siEzh2 knockdown or the EZH2 degrader DZNep.","dates":{"publication":"2026/07/02"},"accession":"GSE189489","cross_references":{"GSM":["GSM5702493","GSM5702492","GSM5702495","GSM5702484","GSM5702494","GSM5702486","GSM5702485","GSM5702488","GSM5702487","GSM5702491","GSM5702490","GSM5726839","GSM5726838","GSM5726837","GSM5702489"],"GPL":["13112"],"SRA":["SRP347616"],"GSE":["189489"],"taxon":["Mus musculus"]}}